Table 4.
Logistic regression predicting the likelihood of responding to therapy with anti-CGRP/R mAbs at baseline (responders vs non-responders).
| p | OR | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Sex | 0.223 | 0.406 | 0.095 | 1.731 |
| Age | 0.225 | 1.030 | 0.982 | 1.081 |
| ASC12 | 0.619 | 1.036 | 0.901 | 1.191 |
| FSS | 0.374 | 0.978 | 0.932 | 1.027 |
| GAD7 | 0.485 | 1.070 | 0.885 | 1.292 |
| PHQ9 | 0.158 | 0.886 | 0.748 | 1.048 |
FSS: Fatigue Severity Scale; ASC-12: Allodynia Symptom Checklist 12; GAD7: Generalized Anxiety Disorder 7; PHQ9: Patient Health Questionnaire 9; OR: odds ratio.